Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 15 Mar 2023
A world first: A research team from Tel Aviv University and the Israel Institute of Biology has developed an anti-mRNA drug that is 100% effective against a single type of virus.
Read Full NewsNon-Factor Therapies in Hemophilia: Cutting-Edge Approaches to Individualize Care
Precision Medicine in mHSPC: Integrating Novel Biomarkers, Imaging, and Emerging Targeted Agents
Accelerating the Evidence-Based Integration of Menin Inhibitors Into R/R AML Care: A Live Expert TheraTalk
Frontline Decisions in Transplant-Ineligible Multiple Myeloma: Evaluating Quadruplet Therapy
1.
Risk of a second cancer after early breast cancer is low, say new findings
2.
Atezolizumab Consolidation Impresses in High-Risk DLBCL
3.
WHO launches plan for free child cancer medicines
4.
Lentiviral Gene Therapy Shows Promise in Severe Hemophilia A
5.
Additional imaging techniques can detect early stage cancers missed by mammograms in women with dense breasts
1.
Expanding Oncology Frontiers: Rare Cancers, Breakthroughs, and Precision Medicine Advances
2.
Exploring New Solutions for MCV Low: Unlocking the Potential for Improved Health
3.
Navigating the Evolving Landscape of Oncology Clinical Trials in the Era of Precision Medicine
4.
Exploring the Potential of Bendamustine in Cancer Treatment
5.
The Dark Side of Melanoma: Uncovering the Risk Factors and Prevention Strategies
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Iron Deficiency Anemia: Ferric Maltol As a New Treatment Option- Summarization of the New Perspective
2.
Role of Nimotuzumab in Management of Nasopharyngeal Cancer
3.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part VI
4.
Expert Group meeting with the management of EGFR mutation positive NSCLC - Part I
5.
Redefining Treatment Pathways in Relapsed/Refractory Adult B-Cell ALL
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge